Copy to clipboard 
While COVID-19 cases have declined and restrictions have eased, especially in the U.S., pandemic ramifications remain present in the minds of orthopedic leaders. In recent earnings calls, executives at public companies of all sizes were cautiously optimistic about the market performing better in 2022 than in 2021. Healthcare staffing shortages, supply chain challenges and potential new variants were the primary headwinds leaders that pointed to when discussing their outlook for 2022.
Our latest infographic highlights comments from DePuy Synthes, Zimmer Biomet, NuVasive and ConMed, among others.
Infographic proudly sponsored by Intech
Since COVID-19 was officially named a pandemic by the World Health Organization in March 2020, companies have exercised incredible flexibility with their teams, supply chains, clinical trials and so on. Orthopedic executives noted the need for their companies to remain adaptable throughout 2022.
